Business Context and Reporting Period
This Form 8-K filing by Rexahn Pharmaceuticals, Inc. (not Opus Genetics, Inc.) reports a material definitive agreement entered into on October 10, 2013. The report was filed on October 16, 2013, detailing a registered direct public offering of common stock and warrants to institutional investors.
Key Financial Metrics
- Gross Proceeds: Approximately $5.3 million from the sale of 10,192,309 shares of common stock and warrants to purchase 3,567,309 shares.
- Net Proceeds: Expected to be approximately $4.8 million after deducting placement agent fees, expenses, and estimated offering costs.
- Offering Price: $0.52 per unit (one share of common stock plus a warrant to purchase 0.35 shares).
- Warrant Terms: Exercise price of $0.575 per share; exercisable beginning six months after issuance; expiration five years from issuance.
- Placement Agent Fees: 6% of gross proceeds plus a warrant for 407,692 shares (4% of aggregate shares sold) and expense reimbursement up to $50,000 (1% of gross proceeds).
Material Changes
The filing discloses a significant capital raise event rather than operational performance changes. The company is issuing new equity and warrants, which will increase the total number of outstanding shares and warrants. The filing does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a transactional report.
Outlook, Risks, and Management Commentary
The offering is expected to close on or about October 16, 2013, subject to customary closing conditions. The net proceeds are intended to fund the company's operations, though specific allocation details are not provided in this text. The filing includes standard legal disclaimers stating that representations and warranties in the purchase agreement are not for the benefit of the public and that investors should rely on other SEC filings for factual information about the company's current state.
Investor Verification Checklist
- Verify the exact closing date of the offering and confirmation of the $4.8 million net proceeds.
- Review the company's most recent 10-Q or 10-K to assess current cash runway and burn rate relative to the new capital.
- Confirm the total number of outstanding shares post-offering to calculate potential dilution impact.
- Check for any subsequent filings regarding the use of proceeds or changes in the company's strategic direction.
- Note the discrepancy in the request metadata: the filing is for Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.